CRISPR Therapeutics AG(CRSP)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
CRSP | 4.82 B | - | 1041.40% | 0.00% | -$4.75 | -26.10% | 0.45x | 0.00% | $75.06 | $44.12 |
688235.SS | 30.14 B | 85.06x | 29.60% | 10.70% | $3.08 | 14.66% | 0.40x | 0.00% | $319.24 | $205.51 |
IDIA.SW | 1.14 B | - | -26.80% | -158.32% | -$1.38 | - | - | 0.00% | $7.56 | $2.80 |
MLTX | 878.3 M | - | - | 0.00% | -$3.78 | -67.48% | 0.24x | 0.00% | $23.29 | $8.80 |
KURN.SW | 743.1 M | 110.18x | 45.50% | 5.13% | $0.17 | 10.73% | 0.11x | 0.00% | $34.20 | $16.46 |
Peer Valuation & Performance Analysis
Peer group analysis for CRISPR Therapeutics AG (CRSP) compared to its primary competitors (including 688235.SS, IDIA.SW, MLTX) reveals distinct metrics. CRSP trades at a valuation discount relative to its competitors, with a P/E ratio of -10.5x versus the peer average of 47.4x (representing a 122% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, CRSP's revenue growth of 1041.4% exceeds the peer average of 16.1%, highlighting its competitive strength and market share gains. Additionally, it boasts superior profitability with a net margin of 0.0% compared to the peer average of -35.6%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• CRSP ranks #0 in P/E ratio, #1 in revenue growth, and #3 in profit margins
• Average ranking: #1 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $48.87 | $50.33 | $47.36 | $49.88 | 2,155,136 | -0.32% |
| 2026-10-19 | $49.83 | $50.30 | $49.09 | $50.04 | 1,172,500 | +1.60% |
| 2026-10-16 | $51.20 | $51.36 | $49.05 | $49.25 | 1,518,000 | -4.41% |
| 2026-10-15 | $50.00 | $52.37 | $49.76 | $51.52 | 1,352,700 | +2.59% |
| 2026-10-14 | $49.67 | $50.78 | $48.91 | $50.22 | 1,703,000 | +0.24% |
| 2026-10-13 | $51.01 | $51.11 | $49.77 | $50.10 | 1,340,800 | -2.81% |
| 2026-10-12 | $52.91 | $53.21 | $51.40 | $51.55 | 1,103,600 | -3.45% |
| 2026-10-09 | $50.82 | $54.07 | $50.52 | $53.39 | 1,465,700 | +5.85% |
| 2026-10-08 | $51.51 | $53.54 | $50.02 | $50.44 | 2,863,400 | -3.65% |
| 2026-10-07 | $53.00 | $54.59 | $52.27 | $52.35 | 1,679,200 | -3.06% |
| 2026-10-06 | $60.38 | $60.68 | $53.74 | $54.00 | 2,622,800 | -5.82% |
| 2026-10-05 | $55.21 | $57.46 | $54.01 | $57.34 | 1,701,300 | +3.45% |
| 2026-10-02 | $56.45 | $57.58 | $54.09 | $55.43 | 1,128,300 | -0.02% |
| 2026-10-01 | $55.45 | $56.59 | $54.82 | $55.44 | 1,058,000 | +0.22% |
| 2026-09-30 | $56.55 | $57.11 | $55.28 | $55.32 | 1,165,000 | -1.21% |
Explore More Analysis for CRSP
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.